1DHR Stock Chart & Stats
€169.00
€2.35(1.41%)
At close: 4:00 PM EDT
€169.00
€2.35(1.41%)
Day’s Range― - ―
52-Week Range€93.00 - €308.00
Previous CloseN/A
Volume176.00
Average Volume (3M)43.00
Market Cap
€118.85B
Enterprise Value€162.35K
Total Cash (Recent Filing)€4.35B
Total Debt (Recent Filing)€26.56B
Price to Earnings (P/E)34.5
Beta0.45
Next Earnings
Oct 27, 2026EPS Estimate
1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.65
Shares Outstanding702,986,100
10 Day Avg. Volume100
30 Day Avg. Volume43
Financial Highlights & Ratios
PEG Ratio-9.26
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€190.90Price Target Upside12.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)7.37
Revenue Forecast (FY)€22.78B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowConsistent, high free cash flow (TTM ~$5.5B; strong YTD conversion) provides durable funding for R&D, targeted M&A, debt servicing, and shareholder returns. Reliable FCF underpins strategic flexibility and de-risks capital allocation over the next several quarters.
Recurring Consumables & ServicesA business model driven by installed-equipment consumption, reagents, software and service contracts yields repeatable revenue and high customer switching costs. This recurring mix supports margin stability and predictable cashflows across 2–6 months and beyond.
Active M&A And Secured FinancingRecent accretive deals (Masimo closed), a pipeline add-on (StatLab) and a multi‑tranche CHF note issuance create strategic optionality. Low‑cost, long‑dated financing plus disciplined integration can expand recurring revenues and accelerate durable portfolio-driven growth.
Bears Say
Modest Revenue GrowthTop-line growth has been tepid (low single digits TTM) while ROE and margins have normalized from prior peaks. Slower organic growth limits operating leverage and constrains faster EPS expansion absent continued M&A or higher-margin product mix shifts.
Bioprocessing Timing RiskLarge customer shipment delays and site‑readiness uncertainty created multi‑quarter revenue rebasings (~$50–$60M Q2 impact; >$100M shifted). Such lumpy timing undermines quarter-to-quarter visibility and can depress near‑term utilization and consumables cadence.
Respiratory Mix HeadwindCyclical declines in respiratory testing volumes create meaningful mix and margin pressure (management cites ~250bps headwind and a 20bp margin decline). Dependence on volume‑sensitive diagnostics segments adds persistent revenue and margin volatility.
Danaher News
1DHR FAQ
What was Danaher Corp.’s price range in the past 12 months?
Danaher Corp. lowest stock price was €93.00 and its highest was €308.00 in the past 12 months.
What is Danaher Corp.’s market cap?
Danaher Corp.’s market cap is €118.85B.
When is Danaher Corp.’s upcoming earnings report date?
Danaher Corp.’s upcoming earnings report date is Oct 27, 2026 which is in 83 days.
How were Danaher Corp.’s earnings last quarter?
Danaher Corp. released its earnings results on Jul 21, 2026. The company reported €1.685 earnings per share for the quarter, beating the consensus estimate of €1.608 by €0.077.
Is Danaher Corp. overvalued?
According to Wall Street analysts Danaher Corp.’s price is currently Undervalued.
Does Danaher Corp. pay dividends?
Danaher Corp. does not currently pay dividends.
What is Danaher Corp.’s EPS estimate?
Danaher Corp.’s EPS estimate is 1.67.
How many shares outstanding does Danaher Corp. have?
Danaher Corp. has 702,986,100 shares outstanding.
What happened to Danaher Corp.’s price movement after its last earnings report?
Danaher Corp. reported an EPS of €1.685 in its last earnings report, beating expectations of €1.608. Following the earnings report the stock price went down -14.27%.
Which hedge fund is a major shareholder of Danaher Corp.?
Currently, no hedge funds are holding shares in IT:1DHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€190.90 (12.96% Upside)
€190.90 (12.96% Upside)
Blogger Sentiment
Bullish
IT:1DHR Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €206.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.87%
12-Months-Change
Fundamentals
Return on Equity
0.74%
Trailing 12-Months
Asset Growth
13.17%
Trailing 12-Months
Company Description
Danaher Corp.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
1DHR Company Deck
1DHR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: revenue and core growth accelerated sequentially (core ex-respiratory +4.5%), EPS grew ~8% and guidance was raised, cash generation was strong (Q2 FCF $1.3B, YTD conversion 124%), and life sciences and diagnostics showed solid performance with several product and M&A catalysts (Masimo closed early and is accretive; StatLab acquisition announced). Key challenges include bioprocessing shipment timing that pushed just over $100M into next year, respiratory-related headwinds (notably in Q3), modest margin pressure (down 20 bps), and continued softness in academic funding. On balance the positive operational execution, cash generation, guidance raise, and strategic M&A/repurchases outweigh the near-term timing and respiratory headwinds.View all IT:1DHR earnings summaries1DHR Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics
1DHR Stock 12 Month Forecast
Average Price Target
€190.90
▲(12.96% Upside)